Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Minoryx Therapeutics
Biotech
Minoryx knocked back by EMA but vows to seek rerun of review
EMA swatted away Minoryx’s attempt to bring a rare disease candidate to market on the strength of a clinical trial that missed its primary endpoint.
Nick Paul Taylor
Jan 26, 2024 8:40am
Minoryx pockets €51M to guide rare disease drug to market
May 31, 2022 10:00am
Roche-backed Minoryx raises €21M to expand CNS R&D
Sep 26, 2018 8:50am
EuroBiotech: More Articles of Note
Feb 22, 2018 10:00am
Novartis, Sanofi-backed NeuroVia closes $14M series A
Jul 20, 2017 7:30am